Power3 Medical Products, Inc. (OTCBB: PWRM – News) announced today that it has filed two provisional patent applications with the United States Patent and Trademark Office (USPTO) – one on Alzheimer's disease specific differential diagnosis in the clinical setting and the other on important differences in pathophysiology and therapeutic options for the genetically distinct groups of Alzheimer's disease patients.

?These two provisional patent applications, along with the additional provisional patent application recently filed by the principals of Power3 and others (Business Wire, May 4, 2010) on the use of stem cell protein biomarkers to monitor stem cell therapy and three other recently filed provisional patent applications on Parkinson's and Alzheimer's disease diagnosis, disclose a vast amount of invaluable information crucial to the accurate diagnosis and treatment of neurodegenerative diseases,? stated Ira L. Goldknopf, Ph.D., President and Chief Scientific Officer of Power3 Medical Products, Inc. ?These provisional patent applications cover diagnosis, treatment options and therapy monitoring in neurodegenerative diseases. The combination of these disclosures forms a strong foundation for innovation in diagnosis and treatment for Alzheimer's disease, and other diseases, through the genome and proteome of the patient, i.e., Personalized Regenerative Medicine (PRM?).?

Power3 Medical Products

Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig's disease). Power3 applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 has developed a portfolio of products including BC-SeraPro?, a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials, and NuroPro®, a serum test for the detection of neurodegenerative diseases, including Alzheimer's, Parkinson's and ALS diseases, currently engaged in Phase II clinical trials. These products are designed to analyze proteins and their mutations to assess an individual's risk for developing disease later in life, a patient's likelihood of responding to a particular drug, a patient's risk of disease progression and disease recurrence, to measure a patient's exposure to drug therapy, to ensure optimal dosing and reduced drug toxicity.

For more information, please visit http://www.power3medical.com.

Safe Harbor Provision

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact contained herein, including, without limitation, statements regarding the company's future financial position, business strategy, budgets, projected revenues and costs, and plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "will," "expects," "intends," "plans," "projects," "estimates," "anticipates," or "believes" or the negative thereof or any variation thereon or similar terminology or expressions. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from results proposed in such statements. Although the company believes that the expectations reflected in such forward-looking statements are reasonable, it can provide no assurance that such expectations will prove to have been correct. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors set forth in the company's Annual Report on Form 10-K for the year ended December 31, 2009 and its other filings and submissions with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made. Except as required by law, the company assumes no obligation to update or revise any of the information contained in this press release.

Crown Equity Holdings, Inc.
Ken Bosket, (877) 854-6797, (702) 448-1543